MedTrace Logo

A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)

NCT04107961 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-09-30

No results posted yet for this study

Summary

The actual format of the anticipated LEISH3 trial is under review.

Conditions

  • Post-kala-azar Dermal Leishmaniasis

Interventions

BIOLOGICAL

Vaccine

Single intramuscular injection into the deltoid region

OTHER

Placebo

Single intramuscular injection into the deltoid region

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • European and Developing Countries Clinical Trials Partnership (EDCTP)

    collaborator OTHER_GOV

  • European Vaccine Initiative

    collaborator OTHER

  • University of York

    lead OTHER

Principal Investigators

  • Paul M Kaye, PhD · University of York

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-12-31
Completion
2025-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04107961 on ClinicalTrials.gov